BG61383B1 - Pharmacetical preparations - Google Patents

Pharmacetical preparations Download PDF

Info

Publication number
BG61383B1
BG61383B1 BG97644A BG9764493A BG61383B1 BG 61383 B1 BG61383 B1 BG 61383B1 BG 97644 A BG97644 A BG 97644A BG 9764493 A BG9764493 A BG 9764493A BG 61383 B1 BG61383 B1 BG 61383B1
Authority
BG
Bulgaria
Prior art keywords
pharmaceutically active
active substance
fatty acid
pharmaceutical preparation
preparation according
Prior art date
Application number
BG97644A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG97644A (bg
Inventor
Stephen G Barnwell
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of BG97644A publication Critical patent/BG97644A/bg
Publication of BG61383B1 publication Critical patent/BG61383B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Laminated Bodies (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
BG97644A 1990-10-19 1993-04-16 Pharmacetical preparations BG61383B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909022788A GB9022788D0 (en) 1990-10-19 1990-10-19 Pharmaceutical formulations
PCT/GB1991/001824 WO1992006680A1 (en) 1990-10-19 1991-10-18 Biphasic release formulations for lipophilic drugs

Publications (2)

Publication Number Publication Date
BG97644A BG97644A (bg) 1994-04-29
BG61383B1 true BG61383B1 (en) 1997-07-31

Family

ID=10684032

Family Applications (1)

Application Number Title Priority Date Filing Date
BG97644A BG61383B1 (en) 1990-10-19 1993-04-16 Pharmacetical preparations

Country Status (21)

Country Link
US (1) US5391377A (hu)
EP (1) EP0553178B1 (hu)
JP (1) JP3276368B2 (hu)
KR (1) KR100188642B1 (hu)
AT (1) ATE122881T1 (hu)
AU (1) AU656924B2 (hu)
BG (1) BG61383B1 (hu)
CA (1) CA2093206C (hu)
CZ (1) CZ282822B6 (hu)
DE (1) DE69110052T2 (hu)
DK (1) DK0553178T3 (hu)
ES (1) ES2073177T3 (hu)
FI (1) FI104408B (hu)
GB (1) GB9022788D0 (hu)
HK (1) HK85296A (hu)
HU (2) HUT64215A (hu)
NO (1) NO305505B1 (hu)
RO (1) RO114739B1 (hu)
RU (1) RU2121344C1 (hu)
SK (1) SK279845B6 (hu)
WO (1) WO1992006680A1 (hu)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
DE4443175A1 (de) * 1994-12-05 1996-06-13 Jenapharm Gmbh Neue pulsatile Arzneiform
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
EP0808154B1 (en) * 1995-02-06 2000-12-20 Elan Pharma International Limited Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6024980A (en) * 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
IL123505A (en) 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20030008919A1 (en) * 1999-06-03 2003-01-09 Jean-Baptiste Roullet Use of retinoids to treat high blood pressure and other cardiovascular disease
EP1049475A4 (en) 1998-01-08 2003-06-04 Univ California MODULATORS OF THE KINESINE ENGINE DERIVED FROM THE SEA SPONGE $ i (ADOCIA)
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
BR9916063A (pt) 1998-12-11 2002-01-22 Pharmasolutions Inc Composições auto-emulsificantes para medicamentos fracamente solúveis em água
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US20020132001A1 (en) * 2000-05-11 2002-09-19 Garthwaite Susan M. Aldosterone antagonist composition for release during aldosterone acrophase
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
WO2003084518A2 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040077621A1 (en) * 2002-08-08 2004-04-22 Academia Sinica Antioxidants
US20040248850A1 (en) * 2003-02-11 2004-12-09 Kemia, Inc. Compounds for the treatment of HIV infection
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US20050186262A1 (en) * 2004-01-14 2005-08-25 James Osborne Transdermal delivery device for dihydropyridine type calcium antagonists
CA2556220A1 (en) * 2004-02-11 2005-08-25 Athpharma Limited Chronotherapeutic compositions and methods of their use
US8741635B2 (en) 2004-05-12 2014-06-03 The Walter And Eliza Hall Institute Of Medical Research Method of cell isolation
US8119601B2 (en) * 2005-03-10 2012-02-21 Ben-Gurion University Of The Negev Research And Development Authority Ltd. Voltage dependent anion channel (VDAC1) compositions and methods of use thereof for regulating apoptosis
US8648045B2 (en) 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
MX2007013430A (es) 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
DK1910535T3 (en) 2005-06-24 2016-09-26 The Walter And Eliza Hall Inst Of Medical Res Therapeutic pro-apoptotic BH-3-like molecules and method of forming and / or selecting the same
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
NZ569697A (en) 2006-01-20 2012-01-12 Women S & Children S Health Res Inst Method of treatment, prophylaxis and diagnosis of pathologies of the bone by the modulation of GPC3
US8440788B2 (en) * 2006-04-06 2013-05-14 Ben-Gurion University Of The Negev Research And Development Authority Ltd. N-terminal VDAC variants and uses thereof
WO2007123153A1 (ja) * 2006-04-19 2007-11-01 Ono Pharmaceutical Co., Ltd. 経口投与用カプセル
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
CN101495150B (zh) * 2006-08-01 2011-06-01 大塚制药株式会社 药理活性物质的吸收性被改善的药物组合物
CA2667925A1 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica N.V. Dry granulated pharmaceutical compositions and methods for producing same
WO2008157776A2 (en) * 2007-06-21 2008-12-24 Angelica Therapeutics, Inc. Modified diphtheria toxins
JP5312459B2 (ja) 2007-08-02 2013-10-09 ジリード バイオロジクス，インク． Ｌｏｘおよびｌｏｘｌ２阻害剤ならびにこれらの使用
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
JP2010538005A (ja) * 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
PL2205245T3 (pl) * 2007-10-03 2015-12-31 Wista Lab Ltd Zastosowanie terapeutyczne diaminofenotiazyn
EP2268297A4 (en) 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
US8715722B2 (en) * 2008-05-12 2014-05-06 Capsugel Belgium Nv Capsule with air-vents
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
CN102711809B (zh) 2009-08-17 2015-09-30 特雷康制药公司 使用抗-内皮因子抗体和抗-vegf剂联合治疗癌症
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
ES2363965B1 (es) * 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US9249189B2 (en) 2010-01-18 2016-02-02 Albany Medical College Alpha-fetoprotein “ring and tail” peptides
NZ606880A (en) 2010-08-27 2015-01-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
EP2627349B1 (en) 2010-10-15 2016-02-03 The Trustees of Columbia University in the City of New York Obesity-related genes and their proteins and uses thereof
AU2012249301A1 (en) 2011-04-29 2013-11-21 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
WO2013049749A2 (en) * 2011-09-29 2013-04-04 Plx Pharma Inc. pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
US9550836B2 (en) 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
EA201491599A1 (ru) 2012-02-29 2015-05-29 Джилид Байолоджикс, Инк. Антитела к матриксной металлопротеиназе 9
WO2013128453A1 (en) 2012-03-01 2013-09-06 Yeda Research And Development Co. Ltd. Regeneration of islet beta cells by hsp60 derived peptides
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
JP2015524397A (ja) 2012-07-20 2015-08-24 ラトローブ ユニヴァーシティ 診断及び処置の方法
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
JP6570511B2 (ja) 2013-03-14 2019-09-04 ユーエイビー リサーチ ファンデーション アポリポタンパク質模倣体及びその使用
DK2968503T3 (en) 2013-03-15 2018-12-03 Intrinsic Lifesciences Llc ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
WO2014144708A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． 改質された毒素
US9758559B2 (en) 2013-07-25 2017-09-12 B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University Short peptides derived from VDAC1, compositions and methods of use thereof
WO2015092792A1 (en) 2013-12-20 2015-06-25 Yissum Research Develoment Company Of The Hebrew University Of Jerusalem Ltd. Pro-angiogenic peptides and peptide conjugates
MX2016011177A (es) 2014-02-27 2016-12-16 Gilead Sciences Inc Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
SG11201609522TA (en) 2014-06-11 2016-12-29 Gilead Sciences Inc Methods for treating cardiovascular diseases
JP6587677B2 (ja) 2014-07-17 2019-10-16 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド 魚の生殖におけるニューロキニンｂのアンタゴニスト
US10793614B2 (en) 2014-07-17 2020-10-06 Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. Antagonists of fish reproduction
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
PL3307322T3 (pl) 2015-09-04 2021-07-05 Primatope Therapeutics Inc. Humanizowane przeciwciała anty-cd40 i ich zastosowania
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
ES2959601T3 (es) 2015-10-27 2024-02-27 Univ Queensland Un polipéptido EphA4 modificado
US11034739B2 (en) 2015-11-13 2021-06-15 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases
WO2017106566A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
WO2017177179A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
US11154591B2 (en) 2016-10-14 2021-10-26 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
EP3574003A4 (en) 2017-01-30 2020-12-02 Hudson Institute of Medical Research TREATMENT PROCEDURES
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
KR20230008254A (ko) 2017-11-08 2023-01-13 바이오엔테크 유에스 인크. T 세포 제조 조성물 및 방법
KR20220048988A (ko) 2019-06-11 2022-04-20 마이얼로이드 테라퓨틱스, 인크. 대식세포 특이적 인게이저 조성물 및 이의 사용 방법
JP2022536695A (ja) 2019-06-12 2022-08-18 ビオンテック ユーエス インコーポレイテッド 新抗原組成物およびその使用
JP2023518822A (ja) * 2020-03-26 2023-05-08 ピーエルエックス オプコ インコーポレイテッド ｐＨ依存的再構築が可能な医薬キャリア、その製造方法及び使用方法
AU2021325081A1 (en) 2020-08-13 2023-04-13 Biontech Us Inc. T cell manufacturing compositions and methods
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1600639A (en) * 1978-05-23 1981-10-21 Kali Chemie Pharma Gmbh Medicament preparation having resorption properties and method of producing the same
US4916230A (en) * 1984-07-02 1990-04-10 Merck & Co., Inc. Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
IT1200178B (it) * 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
US5229422A (en) * 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
EP0351897A3 (en) * 1988-06-17 1990-03-21 The Procter & Gamble Company Skin penetration system for salts of amine-functional drugs
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB8909022D0 (en) * 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
DK0553178T3 (da) 1995-07-24
FI931745A0 (fi) 1993-04-16
DE69110052D1 (de) 1995-06-29
NO931410D0 (no) 1993-04-16
SK36393A3 (en) 1993-07-07
CZ282822B6 (cs) 1997-10-15
BG97644A (bg) 1994-04-29
HUT64215A (en) 1993-12-28
EP0553178B1 (en) 1995-05-24
CZ64193A3 (en) 1994-01-19
CA2093206C (en) 2002-01-29
CA2093206A1 (en) 1992-04-20
FI931745A (fi) 1993-04-16
HU211617A9 (en) 1995-12-28
EP0553178A1 (en) 1993-08-04
WO1992006680A1 (en) 1992-04-30
KR930701989A (ko) 1993-09-08
AU8731591A (en) 1992-05-20
JPH06502143A (ja) 1994-03-10
ES2073177T3 (es) 1995-08-01
AU656924B2 (en) 1995-02-23
RO114739B1 (ro) 1999-07-30
JP3276368B2 (ja) 2002-04-22
ATE122881T1 (de) 1995-06-15
DE69110052T2 (de) 1995-10-05
NO305505B1 (no) 1999-06-14
HU9301121D0 (en) 1993-07-28
FI104408B (fi) 2000-01-31
SK279845B6 (sk) 1999-04-13
RU2121344C1 (ru) 1998-11-10
US5391377A (en) 1995-02-21
KR100188642B1 (ko) 1999-06-01
NO931410L (no) 1993-04-16
GB9022788D0 (en) 1990-12-05
HK85296A (en) 1996-05-24

Similar Documents

Publication Publication Date Title
BG61383B1 (en) Pharmacetical preparations
US11911398B2 (en) Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
US5433951A (en) Sustained release formulation containing captopril and method
EP2279729B1 (en) Controlled release preparations
RU2278657C2 (ru) Предконцентрат микроэмульсии
CA2309836C (en) Drug delivery systems utilizing liquid crystal structures
ES2326783T3 (es) Composiciones de n-benzoilestaurosporina espontaneamente dispersables.
JP6537980B2 (ja) 脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法
JP2005508938A (ja) プロミセル薬学的組成物
JP4656483B2 (ja) 新規な自己乳化薬物送達システム
JP2012502065A (ja) 弱イオン性化合物の剤形
HRP980378A2 (en) Encapsulated solution dosage forms of sertraline
EP4098246A1 (en) Formulation of nintedanib
CZ464299A3 (cs) Želatinové zapouzdření roztokové dávkovači formy sertralinu